FDA approves digital therapeutic that uses TV shows to improve vision in children with lazy eye
The U.S. Food and Drug Administration has approved Luminopia One (Luminopia) as a prescription therapy to improve vision in children with amblyopia (lazy eye), the leading cause of vision loss in children, according to a company press release.
Luminopia One is indicated for improvement in visual acuity in children with amblyopia, aged 4-7, associated with anisometropia and/or with mild strabismus, having received treatment instructions as prescribed by a trained eye-care professional. Luminopia One allows patients to watch therapeutically modified TV shows and movies to improve their vision within a virtual reality (VR) headset. This is the first FDA-approved digital therapeutic for children with amblyopia, and more broadly, the first for a neuro-visual disorder.
Read the full press release here.
Related Content
